Efficacy study of CyberKnife stereotactic radiosurgery combined with CIK cell immunotherapy for advanced refractory lung cancer

Wang,Yuan-Yuan; Wang,Yi-Shan; Liu,Tao; Yang,Ke; Yang,Gui‑Qing; Liu,Han-Chen; Wang,Shan-Shan; Yang,Jia-Lin

doi:10.3892/etm.2012.818

Efficacy study of CyberKnife stereotactic radiosurgery combined with CIK cell immunotherapy for advanced refractory lung cancer

Authors:
- Yuan-Yuan Wang
- Yi-Shan Wang
- Tao Liu
- Ke Yang
- Gui‑Qing Yang
- Han-Chen Liu
- Shan-Shan Wang
- Jia-Lin Yang
View Affiliations

Affiliations: School of the Integration of Traditional and Western Medicine, Binzhou Medical University, Yantai, Shandong 264003, P.R. China, Center for Tumor Treatment of the People's Liberation Army 107th Hospital, Yantai, Shandong 264002, P.R. China, Potenbio Biomedical Technical Company, Shenzhen, Guangdong 518000, P.R. China
Published online on: November 19, 2012 https://doi.org/10.3892/etm.2012.818
Pages: 453-456

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

CyberKnife (CK), hypofractionated stereotactic radiosurgery, is a preferred option for the treatment of advanced refractory lung cancer which is usually inoperable. Cytokine‑induced killer (CIK) cell immunotherapy has a marked radiosensitization effect which aids the elimination of residual tumor cells in distant areas. The main purpose of the present study was to evaluate the clinical efficacy of CK alone and combined with CIK cell therapy for advanced refractory lung cancer. In one year, 22 patients with advanced lung cancer underwent CK therapy at a CyberKnife Center. Of these patients, 11 received CIK cell therapy before or after the CK therapy course. The median prescribed dose in the combined CK and CIK group was 35 Gy (mean, 33.8±5.0 Gy) with a median number of fractions of 5. The median dose for patients who underwent CK alone was 35 Gy (mean, 35.2±6.0 Gy). CIK cell therapy was administered according to the condition of each patient, generally 2 continuous therapeutic sessions in 2 months. The median follow‑up period was 3 months. The preliminary curative efficiency rate was 81.82% for patients who underwent CK/CIK and 72.73% for those who received CK alone, according to radiographic re‑examination (P>0.05). The median improvement in the Karnofsky scores of the CK/CIK group was 20 (18±10.51) compared with 10 (8.6±11.85) for those who underwent CK alone (P<0.05). The median expression of carcinoembryonic antigen (CEA) before and after treatment was 40.81 and 12.21 ng/ml, respectively, for the CK/CIK group compared with 39.04 and 26.36 ng/ml for CK alone. The median percentage of phenotype expression of the CIK cells (CD3+/CD8+ and CD3+/CD56+) in the patients who underwent CK/CIK was recorded as 64.35% (57.08±16.94%) and 15.27% (18.80±7.00%), respectively, prior to transfusion. The preliminary results of the present study suggest that CK combined with CIK cell immunotherapy improved the short‑term outcomes of patients for curative efficacy, Karnofsky scores, tumor marker levels and immune status compared with alternative CK treatments, although further studies are required.

View Figures

View References

1.	Ahn SH, Han MS, Yoon JH, et al: Treatment of stage I non-small cell lung cancer with CyberKnife, image-guided robotic stereotactic radiosurgery. Oncol Rep. 21:693–696. 2009.PubMed/NCBI
2.	Castelli J, Thariat J, Benezery K, et al: Feasibility and efficacy of cyberknife radiotherapy for lung cancer: early results. Cancer Radiother. 12:793–799. 2008.(In French).
3.	Brown WT, Wu X, Wen BC, et al: Early results of CyberKnife image-guided robotic stereotactic radiosurgery for treatment of lung tumors. Comput Aided Surg. 12:253–261. 2007. View Article : Google Scholar : PubMed/NCBI
4.	Brown WT, Wu X, Wen BC, Fowler JF, et al: Lung metastases treated by CyberKnife image-guided robotic stereotactic radiosurgery at 41 months. South Med J. 101:376–382. 2008. View Article : Google Scholar : PubMed/NCBI
5.	Wilcox EE, Daskalov GM, Lincoln H, et al: Comparison of planned dose distributions calculated by Monte Carlo and Ray-Trace algorithms for the treatment of lung tumors with cyberknife: a preliminary study in 33 patients. Int J Radiat Oncol Biol Phys. 77:277–284. 2010. View Article : Google Scholar
6.	Bondiau PY, Doyen J, Mammar H, et al: Reirradiation of spine and lung tumor with CyberKnife. Cancer Radiother. 14:438–441. 2010.(In French).
7.	Liu P, Chen L and Huang X: The antitumor effects of CIK cells combined with docetaxel against drug-resistant lung adenocarcinoma cell line SPC-A1/DTX in vitro and in vivo. Cancer Biother Radiopharm. 24:91–98. 2009. View Article : Google Scholar : PubMed/NCBI
8.	Tome ME, Frye JB, Coyle DL, et al: Lymphoma cells with increased anti-oxidant defenses acquire chemoresistance. Exp Ther Med. 3:845–852. 2012.PubMed/NCBI
9.	Goldstraw P, Crowley J, Chansky K, et al: The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2:706–714. 2007. View Article : Google Scholar
10.	Gibbs IC and Loo BW Jr: CyberKnife stereotactic ablative radiotherapy for lung tumors. Technol Cancer Res Treat. 9:589–596. 2010. View Article : Google Scholar : PubMed/NCBI
11.	Qiao X, Tullgren O, Lax I, et al: The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer. 41:1–11. 2003. View Article : Google Scholar : PubMed/NCBI
12.	Collins BT, Vahdat S, Erickson K, et al: Radical cyberknife radiosurgery with tumor tracking: an effective treatment for inoperable small peripheral stage I non-small cell lung cancer. J Hematol Oncol. 2:12009. View Article : Google Scholar : PubMed/NCBI
13.	Sharma SC, Ott JT, Williams JB and Dickow D: Clinical implications of adopting Monte Carlo treatment planning for CyberKnife. J App Clin Med Phys. 11:31422010.PubMed/NCBI
14.	Hoogeman M, Prévost JB, Nuyttens J, et al: Clinical accuracy of the respiratory tumor tracking system of the cyberknife: assessment by analysis of log files. Int J Radiat Oncol Biol Phys. 74:297–303. 2009. View Article : Google Scholar : PubMed/NCBI
15.	Timmerman R, Paulus R, Galvin J, et al: Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 303:1070–1076. 2010. View Article : Google Scholar : PubMed/NCBI
16.	Whyte RI, Crownover R, Murphy MJ, et al: Stereotactic radiosurgery for lung tumors: preliminary report of a phase I trial. Ann Thorac Surg. 75:1097–1101. 2003. View Article : Google Scholar : PubMed/NCBI
17.	Parkash J: Tumor necrosis factor-α induces transcriptional activation of nuclear factor-κB in insulin-producing β-cells. Exp Ther Med. 2:21–26. 2011.
18.	Unger K, Ju A, Oermann E, et al: CyberKnife for hilar lung tumors: report of clinical response and toxicity. J Hematol Oncol. 22:392010. View Article : Google Scholar : PubMed/NCBI
19.	Brown JM, Diehn M and Loo BW Jr: Stereotactic ablative radiotherapy should be combined with a hypoxic cell radiosensitizer. Int J Radiat Oncol Biol Phys. 78:323–327. 2010. View Article : Google Scholar : PubMed/NCBI
20.	Ballen KK, Colvin G, Dey BR, et al: Cellular immune therapy for refractory cancers: novel therapeutic strategies. Exp Hematol. 33:1427–1435. 2005. View Article : Google Scholar : PubMed/NCBI
21.	Hontscha C, Borck Y, Zhou H, et al: Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol. 137:305–310. 2011. View Article : Google Scholar : PubMed/NCBI
22.	Schmidt-Wolf GD, Negrin RS and Schmidt-Wolf IG: Activated T-cells and cytokine-induced CD3⁺CD56⁺ killer cells. Ann Hematol. 74:51–56. 1997. View Article : Google Scholar : PubMed/NCBI
23.	Leemhuis T, Wells S, Scheffold C, et al: A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 11:181–187. 2005. View Article : Google Scholar : PubMed/NCBI
24.	Schmidt-Wolf IG, Negrin RS, Kiem HP, et al: Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 174:139–149. 1991. View Article : Google Scholar
25.	Baker J, Verneris MR, Ito M, et al: Expansion of cytolytic CD8(+) natural killer T-cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood. 97:2923–2931. 2001.
26.	Verneris MR, Kornacker M, Mailänder V and Negrin RS: Resistance of ex vivo expanded CD3⁺CD56⁺ T-cells to Fas-mediated apoptosis. Cancer Immunol Immunother. 49:335–345. 2000. View Article : Google Scholar : PubMed/NCBI